Question 1

How does tirzepatide compare to semaglutide?

Accepted Answer

Tirzepatide shows greater weight reduction (~22% vs ~17%) and comparable glycemic control in head-to-head trials, likely due to the additive GIP receptor component.

Question 2

Is tirzepatide FDA-approved?

Accepted Answer

Yes. As Mounjaro for T2D (2022) and Zepbound for obesity (2023).

Question 3

Why does dual agonism work better?

Accepted Answer

GIP receptor activation adds insulin sensitivity improvement and adipose tissue remodeling that GLP-1 alone does not provide.

What is Tirzepatide - Peptide Encyclopedia